Skip to main content
Top
Published in: Advances in Therapy 12/2019

Open Access 01-12-2019 | Statins | Original Research

Gender Disparities in Health Resource Utilization in Patients with Atherosclerotic Cardiovascular Disease: A Retrospective Cross-Sectional Study

Authors: Xian Shen, Stefan DiMario, Kiran Philip

Published in: Advances in Therapy | Issue 12/2019

Login to get access

Abstract

Introduction

Gender disparities in access to healthcare have been documented, including disparities in access to care for cardiovascular diseases (CVDs). Disparities in access to cardiologists could disadvantage some patients to the newer lipid-lowering proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9i) antibodies, as utilization management criteria for PCSK9is often require step therapy with statins and/or ezetimibe and prescription by a cardiologist. To assess whether these utilization management criteria disproportionally limit access to patients with certain characteristics, we assessed the use of cardiologist care and receipt of statin and/or ezetimibe prescriptions from a cardiologist by gender and other patient demographic and clinical characteristics.

Methods

This cross-sectional study used administrative claims data from Inovalon’s Medical Outcomes Research for Effectiveness and Economics Registry (MORE2 Registry®) for patients enrolled in commercial and Medicare Advantage healthcare plans from January 1, 2014, through December 31, 2014. Provider data from the registry were linked to individual demographic and administrative claims data. Logistic regression models were used to assess characteristics associated with outpatient visits to a cardiologist and receipt of a prescription for statin and/or ezetimibe from a cardiologist.

Results

Data from 39,322 patients in commercial plans and 261,898 patients with Medicare Advantage were analyzed. Female gender (vs male) was associated with a significantly lower likelihood of visiting a cardiologist for patients in commercial plans (odds ratio [OR] 0.85; 95% confidence limit [CL] 0.81–0.88) and in Medicare Advantage plans (OR 0.82; 95% CL 0.81–0.83). Female gender was also associated with a lower likelihood of receiving a statin and/or ezetimibe prescription from a cardiologist for patients in commercial plans (OR 0.69; 95% CL 0.65–0.74) and in Medicare Advantage plans (OR 0.78; 95% CL 0.76–0.79).

Conclusions

Compared with men, women were less likely to visit a cardiologist and less likely to receive a prescription for a statin and/or ezetimibe from a cardiologist.

Funding

Amgen Inc.
Literature
1.
go back to reference Wu MY, Li CJ, Hou MF, Chu PY. New insights into the role of inflammation in the pathogenesis of atherosclerosis. Int J Mol Sci. 2017;18:2034.CrossRef Wu MY, Li CJ, Hou MF, Chu PY. New insights into the role of inflammation in the pathogenesis of atherosclerosis. Int J Mol Sci. 2017;18:2034.CrossRef
2.
go back to reference Barquera S, Pedroza-Tobias A, Medina C, et al. Global overview of the epidemiology of atherosclerotic cardiovascular disease. Arch Med Res. 2015;46:328–38.CrossRef Barquera S, Pedroza-Tobias A, Medina C, et al. Global overview of the epidemiology of atherosclerotic cardiovascular disease. Arch Med Res. 2015;46:328–38.CrossRef
3.
go back to reference Benjamin EJ, Muntner P, Alonso A, et al. Heart disease and stroke statistics—2019 update: a report from the American Heart Association. Circulation. 2019;139:e56–528.CrossRef Benjamin EJ, Muntner P, Alonso A, et al. Heart disease and stroke statistics—2019 update: a report from the American Heart Association. Circulation. 2019;139:e56–528.CrossRef
7.
go back to reference Gouni-Berthold I, Descamps OS, Fraass U, et al. Systematic review of published phase 3 data on anti-PCSK9 monoclonal antibodies in patients with hypercholesterolaemia. Br J Clin Pharmacol. 2016;82:1412–43.CrossRef Gouni-Berthold I, Descamps OS, Fraass U, et al. Systematic review of published phase 3 data on anti-PCSK9 monoclonal antibodies in patients with hypercholesterolaemia. Br J Clin Pharmacol. 2016;82:1412–43.CrossRef
8.
go back to reference Stroes E, Robinson JG, Raal FJ, et al. Consistent LDL-C response with evolocumab among patient subgroups in PROFICIO: a pooled analysis of 3146 patients from phase 3 studies. Clin Cardiol. 2018;41:1328–35.CrossRef Stroes E, Robinson JG, Raal FJ, et al. Consistent LDL-C response with evolocumab among patient subgroups in PROFICIO: a pooled analysis of 3146 patients from phase 3 studies. Clin Cardiol. 2018;41:1328–35.CrossRef
9.
go back to reference Vallejo-Vaz AJ, Ginsberg HN, Davidson MH, et al. Lower on-treatment low-density lipoprotein cholesterol and major adverse cardiovascular events in women and men: pooled analysis of 10 ODYSSEY phase 3 alirocumab trials. J Am Heart Assoc. 2018;7:e009221.CrossRef Vallejo-Vaz AJ, Ginsberg HN, Davidson MH, et al. Lower on-treatment low-density lipoprotein cholesterol and major adverse cardiovascular events in women and men: pooled analysis of 10 ODYSSEY phase 3 alirocumab trials. J Am Heart Assoc. 2018;7:e009221.CrossRef
10.
go back to reference Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376:1713–22.CrossRef Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376:1713–22.CrossRef
11.
go back to reference Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379:2097–107.CrossRef Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379:2097–107.CrossRef
12.
go back to reference Baum SJ, Toth PP, Underberg JA, Jellinger P, Ross J, Wilemon K. PCSK9 inhibitor access barriers-issues and recommendations: improving the access process for patients, clinicians and payers. Clin Cardiol. 2017;40:243–54.CrossRef Baum SJ, Toth PP, Underberg JA, Jellinger P, Ross J, Wilemon K. PCSK9 inhibitor access barriers-issues and recommendations: improving the access process for patients, clinicians and payers. Clin Cardiol. 2017;40:243–54.CrossRef
13.
go back to reference Myers KD, Farboodi N, Mwamburi M, et al. Effect of access to prescribed PCSK9 inhibitors on cardiovascular outcomes. Circ Cardiovasc Qual Outcomes. 2019;12:e005404.CrossRef Myers KD, Farboodi N, Mwamburi M, et al. Effect of access to prescribed PCSK9 inhibitors on cardiovascular outcomes. Circ Cardiovasc Qual Outcomes. 2019;12:e005404.CrossRef
15.
go back to reference Roeters van Lennep JE, Westerveld HT, Erkelens DW, van der Wall EE. Risk factors for coronary heart disease: implications of gender. Cardiovasc Res. 2002;53:538–49.CrossRef Roeters van Lennep JE, Westerveld HT, Erkelens DW, van der Wall EE. Risk factors for coronary heart disease: implications of gender. Cardiovasc Res. 2002;53:538–49.CrossRef
16.
go back to reference Cholesterol Treatment Trialistss' (CTT) Collaboration, Fulcher J, O’Connell R, et al. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet. 2015;385:1397–405.CrossRef Cholesterol Treatment Trialistss' (CTT) Collaboration, Fulcher J, O’Connell R, et al. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet. 2015;385:1397–405.CrossRef
17.
go back to reference Lee SK, Khambhati J, Varghese T, et al. Comprehensive primary prevention of cardiovascular disease in women. Clin Cardiol. 2017;40:832–8.CrossRef Lee SK, Khambhati J, Varghese T, et al. Comprehensive primary prevention of cardiovascular disease in women. Clin Cardiol. 2017;40:832–8.CrossRef
18.
go back to reference Aragam KG, Moscucci M, Smith DE, et al. Trends and disparities in referral to cardiac rehabilitation after percutaneous coronary intervention. Am Heart J. 2011;161:544–51.e2. Aragam KG, Moscucci M, Smith DE, et al. Trends and disparities in referral to cardiac rehabilitation after percutaneous coronary intervention. Am Heart J. 2011;161:544–51.e2.
19.
go back to reference Colella TJ, Gravely S, Marzolini S, et al. Sex bias in referral of women to outpatient cardiac rehabilitation? A meta-analysis. Eur J Prev Cardiol. 2015;22:423–41.CrossRef Colella TJ, Gravely S, Marzolini S, et al. Sex bias in referral of women to outpatient cardiac rehabilitation? A meta-analysis. Eur J Prev Cardiol. 2015;22:423–41.CrossRef
20.
go back to reference Sabbag A, Matetzky S, Porter A, et al. Sex differences in the management and 5-year outcome of young patients (< 55 years) with acute coronary syndromes. Am J Med. 2017;130:1324.e15–22.CrossRef Sabbag A, Matetzky S, Porter A, et al. Sex differences in the management and 5-year outcome of young patients (< 55 years) with acute coronary syndromes. Am J Med. 2017;130:1324.e15–22.CrossRef
21.
go back to reference Alnsasra H, Zahger D, Geva D, et al. Contemporary determinants of delayed benchmark timelines in acute myocardial infarction in men and women. Am J Cardiol. 2017;120:1715–9.CrossRef Alnsasra H, Zahger D, Geva D, et al. Contemporary determinants of delayed benchmark timelines in acute myocardial infarction in men and women. Am J Cardiol. 2017;120:1715–9.CrossRef
22.
go back to reference Tran HV, Waring ME, McManus DD, et al. Underuse of effective cardiac medications among women, middle-aged adults, and racial/ethnic minorities with coronary artery disease (from the National Health and Nutrition Examination Survey 2005 to 2014). Am J Cardiol. 2017;120:1223–9.CrossRef Tran HV, Waring ME, McManus DD, et al. Underuse of effective cardiac medications among women, middle-aged adults, and racial/ethnic minorities with coronary artery disease (from the National Health and Nutrition Examination Survey 2005 to 2014). Am J Cardiol. 2017;120:1223–9.CrossRef
23.
go back to reference Shaw LJ, Merz CN, Bittner V, et al. Importance of socioeconomic status as a predictor of cardiovascular outcome and costs of care in women with suspected myocardial ischemia. Results from the National Institutes of Health, National Heart, Lung and Blood Institute-sponsored Women’s Ischemia Syndrome Evaluation (WISE). J Womens Health (Larchmt). 2008;17:1081–92.CrossRef Shaw LJ, Merz CN, Bittner V, et al. Importance of socioeconomic status as a predictor of cardiovascular outcome and costs of care in women with suspected myocardial ischemia. Results from the National Institutes of Health, National Heart, Lung and Blood Institute-sponsored Women’s Ischemia Syndrome Evaluation (WISE). J Womens Health (Larchmt). 2008;17:1081–92.CrossRef
24.
go back to reference Moore JE, Mompe A, Moy E. Disparities by sex tracked in the 2015 National Healthcare Quality and Disparities Report: trends across National Quality strategy priorities, health conditions, and access measures. Womens Health Issues. 2018;28:97–103.CrossRef Moore JE, Mompe A, Moy E. Disparities by sex tracked in the 2015 National Healthcare Quality and Disparities Report: trends across National Quality strategy priorities, health conditions, and access measures. Womens Health Issues. 2018;28:97–103.CrossRef
25.
go back to reference Ladapo JA, Coles A, Dolor RJ, et al. Quantifying sociodemographic and income disparities in medical therapy and lifestyle among symptomatic patients with suspected coronary artery disease: a cross-sectional study in North America. BMJ Open. 2017;7:e016364.CrossRef Ladapo JA, Coles A, Dolor RJ, et al. Quantifying sociodemographic and income disparities in medical therapy and lifestyle among symptomatic patients with suspected coronary artery disease: a cross-sectional study in North America. BMJ Open. 2017;7:e016364.CrossRef
Metadata
Title
Gender Disparities in Health Resource Utilization in Patients with Atherosclerotic Cardiovascular Disease: A Retrospective Cross-Sectional Study
Authors
Xian Shen
Stefan DiMario
Kiran Philip
Publication date
01-12-2019
Publisher
Springer Healthcare
Published in
Advances in Therapy / Issue 12/2019
Print ISSN: 0741-238X
Electronic ISSN: 1865-8652
DOI
https://doi.org/10.1007/s12325-019-01107-0

Other articles of this Issue 12/2019

Advances in Therapy 12/2019 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.